TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

56 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

55 studies on the map

BOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvilleSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnMechanistic Studies of Psilocybin in Headache Disorders — VA Connecticut Healthcare System, West HavenProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixSafety and Efficacy of ONT01 in Lupus — Hospital for Special Surgery, New YorkA Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, PhoenixA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Mayo Clinic Hospital, PhoenixA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Yale-New Haven Children's Hospital - PIN, New HavenClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine — Yale University School of Medicine, New HavenA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Research Site, AnnistonA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — David S Hallegua MD A Professional Corporation, Beverly HillsDoes Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs? — University Medical Center of El Paso, El PasoRandomized Study in Children and Adolescents With Migraine: Acute Treatment — Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Perseverance Research Center, LLC, ScottsdaleQudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old — Upsher-Smith Clinical Trial Site #5, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Rehabilitation & Neurological Services /ID# 248517, HuntsvilleA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonComparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study — Northern Arizona Healthcare, FlagstaffA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, Chandler